JP2015527374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015527374A5 JP2015527374A5 JP2015530072A JP2015530072A JP2015527374A5 JP 2015527374 A5 JP2015527374 A5 JP 2015527374A5 JP 2015530072 A JP2015530072 A JP 2015530072A JP 2015530072 A JP2015530072 A JP 2015530072A JP 2015527374 A5 JP2015527374 A5 JP 2015527374A5
- Authority
- JP
- Japan
- Prior art keywords
- melanoma
- pharmaceutical composition
- composition according
- dabrafenib
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229960002465 dabrafenib Drugs 0.000 claims 4
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261696375P | 2012-09-04 | 2012-09-04 | |
| US61/696,375 | 2012-09-04 | ||
| PCT/US2013/057432 WO2014039375A1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017216933A Division JP6511117B2 (ja) | 2012-09-04 | 2017-11-10 | アジュバント癌治療の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015527374A JP2015527374A (ja) | 2015-09-17 |
| JP2015527374A5 true JP2015527374A5 (enExample) | 2016-10-06 |
Family
ID=50237545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530072A Pending JP2015527374A (ja) | 2012-09-04 | 2013-08-30 | アジュバント癌治療の方法 |
| JP2017216933A Active JP6511117B2 (ja) | 2012-09-04 | 2017-11-10 | アジュバント癌治療の方法 |
| JP2019072361A Active JP6684941B2 (ja) | 2012-09-04 | 2019-04-05 | アジュバント癌治療の方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017216933A Active JP6511117B2 (ja) | 2012-09-04 | 2017-11-10 | アジュバント癌治療の方法 |
| JP2019072361A Active JP6684941B2 (ja) | 2012-09-04 | 2019-04-05 | アジュバント癌治療の方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US20150216868A1 (enExample) |
| EP (2) | EP2892535B1 (enExample) |
| JP (3) | JP2015527374A (enExample) |
| KR (1) | KR102134585B1 (enExample) |
| CN (2) | CN104582706A (enExample) |
| AU (2) | AU2013313050A1 (enExample) |
| BR (1) | BR112015004578A2 (enExample) |
| CA (1) | CA2882437C (enExample) |
| CY (1) | CY1124812T1 (enExample) |
| DK (1) | DK2892535T3 (enExample) |
| ES (1) | ES2900825T3 (enExample) |
| HR (1) | HRP20211817T1 (enExample) |
| HU (1) | HUE056646T2 (enExample) |
| IN (1) | IN2015KN00449A (enExample) |
| LT (1) | LT2892535T (enExample) |
| PL (1) | PL2892535T3 (enExample) |
| PT (1) | PT2892535T (enExample) |
| RU (1) | RU2640180C2 (enExample) |
| SI (1) | SI2892535T1 (enExample) |
| WO (1) | WO2014039375A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013313050A1 (en) | 2012-09-04 | 2015-03-26 | Novartis Ag | Method of adjuvant cancer treatment |
| EP3378952B1 (en) | 2013-12-28 | 2020-02-05 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
| WO2018051306A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| KR20240032157A (ko) * | 2017-05-02 | 2024-03-08 | 노파르티스 아게 | 병용 요법 |
| US11890286B2 (en) * | 2018-04-17 | 2024-02-06 | The University Of Chicago | Methods and compositions for treating cancer |
| CN109106893B (zh) * | 2018-11-12 | 2021-04-20 | 上海市中西医结合医院 | 一种调节肠道屏障功能的中药复方制剂及其制备方法 |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| JP7769388B2 (ja) * | 2019-12-12 | 2025-11-13 | ティン セラピューティクス，インコーポレイテッド | 聴覚損失の予防及び治療のための組成物及び方法 |
| US20250032494A1 (en) | 2021-12-06 | 2025-01-30 | My Personal Therapeutics Ltd | A combination treatment for cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4163738B2 (ja) * | 2004-06-11 | 2008-10-08 | 日本たばこ産業株式会社 | 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物 |
| NZ595313A (en) * | 2005-02-18 | 2013-03-28 | Abraxis Bioscience Llc | The Use Of Nanoparticles Comprising Rapamycin Or Taxane In The Treatment Of Proliferative Diseases |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DK3560498T3 (da) * | 2009-10-16 | 2022-11-14 | Novartis Ag | Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| AU2013313050A1 (en) | 2012-09-04 | 2015-03-26 | Novartis Ag | Method of adjuvant cancer treatment |
-
2013
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en not_active Ceased
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active Active
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
-
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
-
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
-
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
-
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
-
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
-
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
-
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015527374A5 (enExample) | ||
| CY1125292T1 (el) | Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2015523397A5 (enExample) | ||
| JP2015536964A5 (enExample) | ||
| JP2019503365A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR082091A1 (es) | Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion | |
| JP2015532296A5 (enExample) | ||
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| JP2014521735A5 (enExample) | ||
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| JP2015528491A5 (enExample) | ||
| RU2015105821A (ru) | Способ адъювантного лечения рака | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| JP2013541583A5 (enExample) | ||
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| JP2014050390A5 (enExample) | ||
| JP2009515901A5 (enExample) | ||
| JP2015537009A5 (enExample) | ||
| JP2008535785A5 (enExample) | ||
| AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
| JP2009539994A5 (enExample) | ||
| JP2015507020A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2014530181A5 (enExample) |